TRIO Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about TRIO clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 218 trials

Recruiting
Phase 1

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Recurrent Endometrial CarcinomaRecurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Ovarian Clear Cell Adenocarcinoma+6 more
National Cancer Institute (NCI)60 enrolled14 locationsNCT05950464
Recruiting
Phase 3

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+5 more
National Cancer Institute (NCI)360 enrolled409 locationsNCT05256225
Recruiting

Safety, Performance, and Clinical Benefit of Pacing the Left Bundle Branch Area - Post-Market Clinical Follow-up

Sinus Node DysfunctionAtrioventricular BlockBundle-Branch Block+1 more
Boston Scientific Corporation140 enrolled13 locationsNCT07209852
Recruiting
Phase 2

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Recurrent Endometrial CarcinomaEndometrial AdenocarcinomaEndometrial Clear Cell Adenocarcinoma+6 more
National Cancer Institute (NCI)81 enrolled137 locationsNCT05112601
Recruiting
Not Applicable

Efficacy and Tolerability of TENS in Endometriosis-related Pain

EndometriosisPelvic Pain Associated With Endometriosis or AdenomyosisPelvic Pain Associated With Refractory Endometriosis
Monath Electronic92 enrolled1 locationNCT07393295
Recruiting

Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease

Endometrial CancerEndometrioid AdenocarcinomaEndometrial Cancer Stage I
Memorial Sloan Kettering Cancer Center1,715 enrolled19 locationsNCT04291612
Recruiting
Not Applicable

Effect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis

EndometriomaQuality of LifeUltrasound Therapy; Complications+1 more
Hospital Universitari de Bellvitge288 enrolled27 locationsNCT06955221
Recruiting

Intraoperative Ultrasound in Bowel Deep Endometriosis

Deep Infiltrating Endometriosis With or Without Bowel Involvement
Fundacion Dexeus200 enrolled1 locationNCT06876376
Recruiting
Phase 2

Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis

Endometriosis
Mclean Hospital30 enrolled1 locationNCT06477406
Recruiting
Not Applicable

Use of a New Diagnostic Tool in the Detection and Characterization of Endometriosis Lesions

Endometriosis
University Hospital, Toulouse20 enrolled1 locationNCT07053982
Recruiting

Molecular and ctDNA Characterization of High-Risk Endometrial Cancer

Endometrial CarcinomaEndometrial High Grade Endometrioid AdenocarcinomaStage II Endometrial Cancer+2 more
Mayo Clinic100 enrolled1 locationNCT07062016
Recruiting
Phase 3

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Ovarian CarcinomaOvarian High Grade Serous AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+6 more
NRG Oncology880 enrolled676 locationsNCT06580314
Recruiting
Phase 2

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+12 more
Roswell Park Cancer Institute60 enrolled1 locationNCT04919629
Recruiting
Phase 4

Comparison Between Egyptian MTA, Biodentine Versus Calcium Hydroxide as Indirect Pulp Capping Materials In Permanent Teeth

Patient Reported Outcome MeasuresCalcium HydroxideDeep Caries+3 more
Cairo University35 enrolled1 locationNCT06683833
Recruiting

Determination of Lipocalin Type-prostaglandin (L-PGDS) in Blood, Urine, Vaginal Samples and Endometrial Ablation by Enzyme-linked Immunosorbent Assay

EndometriosisAdenomyosis
Centre Hospitalier Universitaire de Nīmes60 enrolled1 locationNCT06864494
Recruiting
Not Applicable

Ablative Technique For Ovarian Preservation In Endometrioma

EndometriomaFertility
Clinique Tivoli Ducos332 enrolled1 locationNCT07119060
Recruiting
Phase 2

A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia

Endometrioid Endometrial Adenocarcinoma
University of Florida20 enrolled1 locationNCT07107334
Recruiting
Phase 2

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Platinum-Sensitive Ovarian CarcinomaRecurrent Ovarian CarcinomaRecurrent Fallopian Tube Carcinoma+12 more
Roswell Park Cancer Institute80 enrolled2 locationsNCT05231122
Recruiting
Not Applicable

Study on the Outcomes of Patients Treated in Gynecological Emergency Departments for Pelvic Endometriosis or Suspected Pelvic Endometriosis

EndometriosisPelvic Pain SyndromeChronic Gynaecological Disease
Centre Hospitalier Intercommunal Creteil200 enrolled1 locationNCT07472842
Recruiting
Phase 2

A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis

Endometriosis
Gesynta Pharma AB190 enrolled30 locationsNCT07260669